Skip to main content

Exagen Inc.

corporate_fare Company Profile

Exagen Inc.

XGN·NASDAQ·Industrial Applications And Services·CIK 0001274737

The company is a medical technology company that designs, develops, and sells innovative testing products under its AVISE® brand. These products are used for the diagnosis, prognosis, and monitoring of complex rheumatic, autoimmune, and autoimmune-related diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's tests are utilized in various clinical settings to aid in decision-making for autoimmune diseases, aiming to improve patient outcomes. The flagship product, AVISE® CTD, was commercially launched in 2012. AVISE® CTD helps differentiate diagnoses for patients with symptoms of various connective tissue diseases (CTDs) and related conditions with overlapping symptoms. This product provides unique biomarkers to assist clinicians in diagnosing CTDs. In 2025, eight new biomarkers were added to the AVISE® CTD panel to enhance its clinical utility in diagnosing SLE and RA. Revenue from AVISE® CTD accounted for 91% of the company's total revenue for both the years ended December 31, 2025, and 2024. Starting in late 2022, the company strengthened its senior leadership team with new members in key roles, including Chief Executive Officer, Chief Financial Officer, Chief Scientific Officer, Vice President of Sales, Vice President of Commercial Strategy, and Medical and Laboratory Director.

Exagen Inc. (NASDAQ:XGN) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 15 items for XGN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 8/10, with 3 rated 8 or above. Recent SEC coverage for XGN spans S-3, 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • Exagen Registers $150M Shelf, Including $50M TD Securities ATM
  • Exagen Registers $150M Shelf With $50M TD Cowen ATM, ~34% Dilution at $5.81
  • Exagen Q3: Revenue Up 7% to $18.4M, Cash Slips to $28.1M as New $50M ATM Launches
  • Exagen Posts 25-Cent Quarterly Loss as Diagnostics Firm's Results Land
  • Exagen Q2 Revenue Jumps 16% on 11% Test Volume Growth, Loss Narrows Sharply

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$66.58M
Net Income
-$19.95M
Diluted EPS
-$0.93
Op. Cash Flow
-$13.63M
Free Cash Flow
-$14.27M
Gross Profit
$38.8M
Operating Income
-$14.07M
Cash & Equivalents
$32.22M
Total Debt
$22.91M
Debt / Equity
1.31×
Net Margin
-30.0%
Shares Outstanding
22.91M sh
Source: 10-K · filed 2026-03-10 · accession 0001274737-26-000009

Short Interest & Short Volume

1.98 days to cover

FINRA reported short interest of 727,455 shares in XGN as of the October 30, 2026 settlement, a 8.0% increase from the prior period — about 2.0 days to cover at its recent average daily volume. On November 20, 2026, 25.8% of XGN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)727,455 shares as of October 30, 2026
Change vs prior period▲ 8.0%
Days to cover1.98 at avg daily volume of 366,878
Daily short volume (FINRA facilities)25.8% of 194,723 shares on November 20, 2026
5-day average short volume26.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for XGN, detected from its recent SEC filings · based on capital-structure filings through 2026-11-17.

1 recent capital raise1 shelf registration

ATM Prospectus Filed for $50M · Share Count and Dilution Math

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with X →
$3.81 +0.26% today
52-week range · as of 2026-11-10 $2.59 – $10.27
Market cap
$92.1M
Volume
508.8K (0.7× avg)
3-mo avg 692.5K
Live data · 2026-11-21 07:40 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed XGN - Latest Insights

XGN
Nov 10, 2026, 9:49 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $5.26
Real-time Price: $3.81 info
Change: -$1.45 (-28%) info
Market Cap: $92.104M info
XGN
Nov 10, 2026, 9:33 AM EST
Filing Type: S-3
Importance Score:
7
Price at Filing: $5.83
Real-time Price: $3.81 info
Change: -$2.02 (-35%) info
Market Cap: $92.104M info
XGN
Nov 10, 2026, 9:01 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $6.55
Real-time Price: $3.81 info
Change: -$2.74 (-42%) info
Market Cap: $92.104M info
XGN
Nov 10, 2026, 7:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.59
Real-time Price: $3.81 info
Change: -$3.78 (-50%) info
Market Cap: $92.104M info
XGN
Aug 04, 2026, 9:15 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $5.66
Real-time Price: $3.81 info
Change: -$1.85 (-33%) info
Market Cap: $92.104M info
XGN
Aug 04, 2026, 8:12 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $5.60
Real-time Price: $3.81 info
Change: -$1.79 (-32%) info
Market Cap: $92.104M info
XGN
Aug 04, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.21
Real-time Price: $3.81 info
Change: -$1.40 (-27%) info
Market Cap: $92.104M info
XGN
Jun 01, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.16
Real-time Price: $3.81 info
Change: -$1.35 (-26%) info
Market Cap: $92.104M info
XGN
May 11, 2026, 9:17 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.30
Real-time Price: $3.81 info
Change: +$0.510 (+15%) info
Market Cap: $92.104M info
XGN
May 11, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.34
Real-time Price: $3.81 info
Change: +$0.4743 (+14%) info
Market Cap: $92.104M info
XGN
May 11, 2026, 8:00 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $3.31
Real-time Price: $3.81 info
Change: +$0.500 (+15%) info
Market Cap: $92.104M info
XGN
Mar 10, 2026, 9:22 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $3.41
Real-time Price: $3.81 info
Change: +$0.4007 (+12%) info
Market Cap: $92.104M info
XGN
Mar 10, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.24
Real-time Price: $3.81 info
Change: +$0.570 (+18%) info
Market Cap: $92.104M info
XGN
Mar 10, 2026, 8:00 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $3.24
Real-time Price: $3.81 info
Change: +$0.570 (+18%) info
Market Cap: $92.104M info
XGN
Jan 12, 2026, 9:03 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.45
Real-time Price: $3.81 info
Change: -$2.64 (-41%) info
Market Cap: $92.104M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets